Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1
Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale.
- Trial name
- NCT03816761
- Testing
- Fast-acting insulin aspart, iLet™
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Changing Diabetes® World Tour
This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01437072
- Testing
- No treatment given
- Where
- 3 sites in Portugal, Saudi Arabia and 1 more
- Volunteers
- 8,304 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in…
- Trial name
- NCT05134662
- Testing
- ALT-801
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Altimmune, Inc.
Diabetes Mellitus, Type 1
Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes
This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a mobile-based novel digital health solution based on emotional and behavioral change…
- Trial name
- CARING-T1D (NCT05483803)
- Testing
- Adhera® Caring digital intervention for Type 1 Diabetes
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Adhera Health, Inc.
Prediabetes, Diabetes Type 1
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions.
- Conditions
- Prediabetes, Diabetes Type 1, Diabetes Type 2
- Trial name
- NCT02057497
- Volunteers
- healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Non-Insulin-dependent Diabetes Mellitus
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2)…
- Trial name
- NCT01582282
- Testing
- 3.4 g psyllium BID, 6.8g psyllium BID
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Procter and Gamble
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients
This trial is a multi-center, open-label, randomized, parallel group trial in adult patients with T1DM comparing the efficacy and safety of GP40071 (insulin aspart, GEROPHARM) with that of NovoRapid®.
- Trial name
- NCT04079413
- Testing
- GP40071, NovoRapid® Penfill®
- Where
- 14 sites in Russia
- Volunteers
- 264 people
- Sponsor
- Geropharm
Diabetic Foot, Foot Ulcer, Diabetic
Use of Santyl in Diabetic Foot Ulcers
This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers…
- Trial name
- NCT02581488
- Testing
- Santyl, Product containing silver
- Where
- 13 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Smith & Nephew, Inc.
Type 1 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.
- Trial name
- INSTRIDE 1 (NCT02227862)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 162 sites in United States, Canada and 9 more
- Volunteers
- 558 people
- Sponsor
- Mylan Inc.
Hypoglycemia
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood…
- Trial name
- AMG102 (NCT01556594)
- Testing
- Nasal Glucagon 1 mg, Nasal Glucagon 2 mg, SC Glucagon
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)
Primary Objective: To characterize the within-subject variability in systemic exposure pharmacokinetic (PK) to insulin of a replicate single dose of Afrezza inhaled Technosphere Insulin (TI) in T1DM patients in a euglycemic clamp…
- Trial name
- NCT02485327
- Testing
- Technosphere Insulin SAR439065 Afrezza®
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus
This is a phase 1, randomized, double-blind, placebo-controlled, 2-center, multiple-dose study in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02430870
- Testing
- TAK-648
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Obesity, Type 2 Diabetes Mellitus
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05184322
- Testing
- T2026, Oral ecnoglutide tablet
- Where
- Australia
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Diabetes, Diabetes Mellitus, Type 1
To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1
This study is conducted in Africa. The aim of this study is to estimate the percentage of children and adolescents below or equal to 15 years in Tunisia with acceptably controlled diabetes mellitus type 1.
- Trial name
- NCT01493388
- Testing
- insulin
- Where
- Tunisia
- Volunteers
- 402 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants…
- Trial name
- EDITION IV (NCT01683266)
- Testing
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Where
- 147 sites in United States, Canada and 11 more
- Volunteers
- 549 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Metronom Continuous Glucose Monitoring System
The aim of the present study is to investigate the clinical performance of the Metronom CGM system in patients with type 1 diabetes over a period of 14 days.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabete Mellitus
- Trial name
- NCT03341026
- Testing
- Metronom CGM device
- Where
- 2 sites in Austria, Denmark
- Volunteers
- 20 people
- Sponsor
- Metronom Health
Type 1 Diabetes Mellitus
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of sotagliflozin following daily oral administration for 29 days in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01742208
- Testing
- Sotagliflozin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus
TAK-329 Glucose Clamp Study
The purpose of this study is to compare the safety, tolerability, pharmacokinetic and pharmacodynamic properties of single doses of TAK-329 with a single dose of a subcutaneously-injected rapid-acting insulin analog in…
- Trial name
- NCT01311076
- Testing
- TAK-329, Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Takeda
Diabetes Mellitus
A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes
Due to continuing technological progress and better understanding of the needs for glucose monitoring, the performance requirements of blood glucose meters, primarily regarding their accuracy, are constantly debated and keep…
- Trial name
- NCT01730885
- Testing
- Comparison of different Blood Glucose Meters
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetic Foot Ulcer, DFU
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
The goal of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks…
- Conditions
- Diabetic Foot Ulcer, DFU, Diabetic Foot Ulcer (DFU), Foot Ulcer Due to Type 1 Diabetes Mellitus
- Trial name
- RENEW (NCT07086443)
- Testing
- Activate™ Matrix, AmnioDefend™ FT Matrix, Palisade™ DM Matrix
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Sequence LifeScience, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.